FDA Grants Priority Review to Genentech Actemra for COVID-19 in Hospitalized

 

• If approved, Actemra would be the first U.S. FDA-approved immunomodulator for the treatment of COVID-19 in hospitalized patients
• Since the beginning of the pandemic, more than one million people hospitalized with COVID-19 have been treated with Actemra worldwide
• Actemra was previously granted Emergency Use Authorization for the treatment of COVID-19 in hospitalized adults and children

https://www.biospace.com/article/releases/u-s-fda-grants-priority-review-to-genentech-s-actemra-for-the-treatment-of-covid-19-in-hospitalized-adults/